Literature DB >> 17898555

[Clinical features and treatment outcome of advanced hepatocellular carcinoma with inferior vena caval invasion or atrial tumor thrombus].

Seung Up Kim1, Yu Ri Kim, Do Young Kim, Ja Kyung Kim, Hyun Woong Lee, Beom Kyung Kim, Kwang Hyub Han, Chae Yoon Chon, Young Myoung Moon, Sang Hoon Ahn.   

Abstract

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) with an extension to the inferior vena cava (IVC) or right atrium is uncommon, and its prognosis remains unclear due to the few case reports. In order to elucidate the natural history and treatment outcome, this study investigated advanced HCC patients with an IVC invasion or atrial tumor thrombus.
METHODS: Between November 1987 and June 2004, a total of 41 patients were diagnosed as having HCC with IVC or right atrial involvement using the new imaging techniques including a two-dimensional echocardiography. Those patients were stratified into the untreated 'control group' (n=17) and 'treated group' (n=24). The clinical features, treatment outcome and prognosis including patient survival were analyzed.
RESULTS: The mean age of the total patients was 55 years (male:female, 33:8). The most common cause of HCC was a hepatitis B virus infection (85.4%), followed by a hepatitis C virus infection (7.4%). According to the Child-Pugh classification, 24 patients were Child-Pugh class A (58.5%), 15 were Child-Pugh class B (36.6%), and 2 were Child-Pugh class C (4.9%). Lung metastases were identified in 10 patients (24.5%). The treatment modalities of the treated group included 11 systemic chemotherapy regimens (5-FU and cisplatin), 10 transarterial chemotherapy regimens, 2 chemoradiation procedures and 1 hepatic resection. The overall survival was 3.0 months (range, 1-29 months). The 6 month survival rate was 23.5% (4/17) in the control group and 29.2% (7/24) in the treated group. The 12 months survival rate was 0% (0/17) and 25.0% (6/24), respectively. Independent prognostic factor affecting the survival was whether or not any treatment had been carried out.
CONCLUSIONS: Although the prognosis of advanced HCC with IVC invasion or a right atrial tumor thrombi is poor, treatment might improve the survival rate.

Entities:  

Mesh:

Year:  2007        PMID: 17898555     DOI: 10.3350/kjhep.2007.13.3.387

Source DB:  PubMed          Journal:  Korean J Hepatol        ISSN: 1738-222X


  6 in total

1.  Intra-atrial tumour thrombus secondary to hepatocellular carcinoma.

Authors:  Hetal Pandya; Chaitri Shah; Jitendra Lakhani; Micky Patel
Journal:  Australas Med J       Date:  2013-06-30

Review 2.  HCC: current surgical treatment concepts.

Authors:  F Cauchy; D Fuks; J Belghiti
Journal:  Langenbecks Arch Surg       Date:  2012-06       Impact factor: 3.445

3.  Progressive dyspnea and a right atrial mass in an 80-year-old man.

Authors:  Vera Demarchi Aiello; Ryan Yukimatsu Tanigawa; Rodrigo Caruso Chate; Fernando Peixoto Ferraz de Campos; Alfredo José Mansur
Journal:  Autops Case Rep       Date:  2019-11-27

4.  Inferior vena cava tumor thrombus that directly infiltrated from paracaval lymph node metastases in a patient with recurrent hepatocellular carcinoma.

Authors:  Shinya Imada; Kohei Ishiyama; Kentaro Ide; Tsuyoshi Kobayashi; Hironobu Amano; Hirotaka Tashiro; Koji Arihiro; Hiroshi Aikata; Kazuaki Chayama; Hideki Ohdan
Journal:  World J Surg Oncol       Date:  2013-08-06       Impact factor: 2.754

5.  Mobile right atrial thrombus with pulmonary thromboembolism in a patient with advanced hepatocellular carcinoma and disseminated tumor thrombosis.

Authors:  Prashanth Panduranga; Mohammed Al-Mukhaini; Lakshmi Ratnam; Salim Al-Harthy
Journal:  Heart Views       Date:  2011-10

6.  Risk factors for patients with stage IVB hepatocellular carcinoma and extension into the heart: prognostic and therapeutic implications.

Authors:  Chung Hwan Jun; Da Woon Sim; Sang Ho Kim; Hyoung Ju Hong; Min Woo Chung; Sung Bum Cho; Chang Hwan Park; Young Eun Joo; Hyun Soo Kim; Sung Kyu Choi; Jong Sun Rew
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.